399 related articles for article (PubMed ID: 30973647)
1. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.
Lunder T; Zorko MS; Kolar NK; Suhodolcan AB; Marovt M; Leskovec NK; Marko PB
Int J Dermatol; 2019 Jun; 58(6):631-641. PubMed ID: 30973647
[TBL] [Abstract][Full Text] [Related]
2. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
[TBL] [Abstract][Full Text] [Related]
3. Drug survival of biologic therapies for the treatment of psoriasis: Results of Slovenian national registry.
Lunder T; Marko P; Koser Kolar N; Kralj B; Kecelj Leskovec N
Biologicals; 2018 Jul; 54():44-49. PubMed ID: 29706309
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
5. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
6. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
[TBL] [Abstract][Full Text] [Related]
7. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Loos AM; Liu S; Segel C; Ollendorf DA; Pearson SD; Linder JA
J Am Acad Dermatol; 2018 Jul; 79(1):135-144.e7. PubMed ID: 29438757
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
10. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
11. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
12. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
[TBL] [Abstract][Full Text] [Related]
14. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
17. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
[TBL] [Abstract][Full Text] [Related]
18. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria.
Inzinger M; Wippel-Slupetzky K; Weger W; Richter L; Mlynek A; Fleischander B; Scheurecker C; Sandor N; Mairhofer D; Sator PG; Moser-Oberthaler S; Häring N; Viznerova P; Painsi C; Tanew A; Ponholzer P; Tatarski R; Brenner W; Stingl G; Salmhofer W; Rappersberger K; Klein G; Saxinger W; Auböck J; Kölli C; Trautinger F; Steiner A; Ratzinger G; Strohal R; Riedl E; Lange-Asschenfeldt B; Pehamberger H; Volc-Platzer B; Selhofer S; Legat FJ; Müllegger R; Reider N; Schmuth M; Hintner H; Hofer A; Gruber-Wackernagel A; Aberer W; Quehenberger F; Wolf P
Acta Derm Venereol; 2016 Feb; 96(2):207-12. PubMed ID: 26271044
[TBL] [Abstract][Full Text] [Related]
19. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]